Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.
Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, Montgomery ND, Bolton KL, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp HS 3rd, Levine RL, Papaemmanuil E, Zehir A, Hayes DN, Padron E. Coombs CC, et al. Among authors: balasis me. Clin Cancer Res. 2018 Dec 1;24(23):5918-5924. doi: 10.1158/1078-0432.CCR-18-1201. Epub 2018 Jun 4. Clin Cancer Res. 2018. PMID: 29866652 Free PMC article.
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).
Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS; Myelodysplastic Syndrome Clinical Research Consortium. Padron E, et al. Among authors: balasis me. Clin Cancer Res. 2016 Aug 1;22(15):3746-54. doi: 10.1158/1078-0432.CCR-15-2781. Epub 2016 Feb 8. Clin Cancer Res. 2016. PMID: 26858309 Free PMC article. Clinical Trial.
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Gillis NK, et al. Among authors: balasis me. Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4. Lancet Oncol. 2017. PMID: 27927582 Free PMC article.
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O. Yoshimi A, et al. Among authors: balasis me. Blood. 2017 Jul 27;130(4):397-407. doi: 10.1182/blood-2017-01-763219. Epub 2017 Jun 2. Blood. 2017. PMID: 28576879 Free PMC article.
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.
Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E. Niyongere S, et al. Among authors: balasis me. Leukemia. 2019 Jan;33(1):205-216. doi: 10.1038/s41375-018-0203-0. Epub 2018 Jul 19. Leukemia. 2019. PMID: 30026572 Free PMC article.
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
Hunter AM, Newman H, Dezern AE, Steensma DP, Niyongere S, Roboz GJ, Mo Q, Chan O, Gerds A, Sallman DA, Dominguez-Viqueira W, Letson C, Balasis ME, Ball M, Kruer T, Zhang H, Lancet JE, List AF, Sekeres MA, Komrokji RS, Padron E. Hunter AM, et al. Among authors: balasis me. Clin Cancer Res. 2021 Nov 15;27(22):6095-6105. doi: 10.1158/1078-0432.CCR-21-0935. Epub 2021 Jul 12. Clin Cancer Res. 2021. PMID: 34253584 Free PMC article. Clinical Trial.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. You X, et al. Blood. 2022 Feb 17;139(7):1066-1079. doi: 10.1182/blood.2021012519. Blood. 2022. PMID: 34699595 Free PMC article.
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.
Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E. Letson CT, et al. Among authors: balasis me. Clin Cancer Res. 2023 Aug 1;29(15):2919-2932. doi: 10.1158/1078-0432.CCR-22-3929. Clin Cancer Res. 2023. PMID: 37223910 Free PMC article.
25 results